NA
FENC icon

NewEdge Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

NewEdge Advisors’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$5 – 3948
2024
Q3 		$5 Sell
1
-1,327
-100% -$7.68K ﹤0.01% 3792
2024
Q2 		$8.12K Buy
+1,328
New +$11K ﹤0.01% 2937

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewEdge Advisors's FENC Position: Q4 2024 in Review

NewEdge Advisors sold out of Fennec Pharmaceuticals (FENC) in Q4 2024, closing a stake of 1 share — an estimated $5 sold.

NewEdge Advisors first reported a position in FENC in Q2 2024 and held it in 2 quarters. The position peaked at $8.12K in Q2 2024. 64 funds tracked by Wall St. Rank hold FENC as of Q4 2024.

  • NewEdge Advisors reported no remaining Fennec Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • NewEdge Advisors sold 1 Fennec Pharmaceuticals share in Q4 2024, an estimated $5.
  • NewEdge Advisors first reported a position in Fennec Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • NewEdge Advisors's Fennec Pharmaceuticals position peaked at $8.12K in Q2 2024.
  • 64 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2024.

Based on NewEdge Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.